Top Page
Oxford BioMedica
(OTC:OXB)
Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford BioMedica Business Overview & Revenue Model
Oxford BioMedica Earnings Call Summary
Oxford BioMedica Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 128.80M | 89.54M | 139.99M | 142.80M | 87.73M | Gross Profit |
| 53.02M | 39.73M | 69.18M | 82.64M | 46.07M | EBIT |
| -39.38M | -184.17M | -51.56M | 20.77M | -4.83M | EBITDA |
| -14.33M | -148.62M | -10.86M | 33.22M | 3.92M | Net Income Common Stockholders |
| -43.19M | -157.49M | -45.16M | 19.01M | -6.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 60.65M | 103.72M | 141.31M | 109.02M | 46.98M | Total Assets |
| 231.64M | 252.34M | 460.18M | 237.23M | 183.93M | Total Debt |
| 108.76M | 111.46M | 114.28M | 9.34M | 13.85M | Net Debt |
| 48.11M | 7.74M | -27.00M | -99.60M | -32.90M | Total Liabilities |
| 171.16M | 174.51M | 223.99M | 49.89M | 71.18M | Stockholders Equity |
| 57.05M | 74.01M | 204.65M | 187.34M | 112.75M |
| Cash Flow | Free Cash Flow | |||
| -58.12M | -38.35M | -28.91M | 15.99M | -10.24M | Operating Cash Flow |
| -50.63M | -28.52M | -12.62M | 25.45M | 3.12M | Investing Cash Flow |
| 5.63M | 2.81M | -56.46M | -9.46M | -10.80M | Financing Cash Flow |
| 2.91M | -12.70M | 98.62M | 46.21M | 38.19M |
Oxford BioMedica Technical Analysis
Oxford BioMedica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | £353.82M | ― | -66.23% | ― | 43.84% | 74.88% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
| £141.02M | ― | -73.02% | ― | ― | ― | ||
65 Neutral | £333.86M | 8.49 | 11.74% | ― | 38.80% | ― | |
46 Neutral | £108.86M | ― | 167.16% | ― | -100.00% | -23.91% | |
| £165.55M | ― | -95.28% | ― | ― | ― | ||
61 Neutral | £1.19B | ― | -23.77% | ― | 7.97% | 12.94% |
Oxford BioMedica Corporate Events
Oxford Biomedica, a leader in cell and gene therapy manufacturing, reports strong commercial momentum and operational progress in 2025, maintaining its financial guidance and outlook set earlier this year. The company continues to support clients across development stages, with no new material information disclosed at the AGM, reinforcing confidence in its near and medium-term targets.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica PLC has announced a change in its voting rights structure following an acquisition by Briarwood Chase Management LLC, a New York-based entity. The acquisition has resulted in Briarwood Chase Management LLC holding 13.0563% of the voting rights in Oxford BioMedica, an increase from the previous 12.019%. This change in voting rights could potentially influence the company’s strategic decisions and impact its market positioning, as stakeholders may see shifts in governance and operational focus.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has applied for a block listing of 250,000 ordinary shares on the London Stock Exchange, as part of its Long Term Incentive Plan. This move is expected to enhance the company’s market presence and provide additional capital for its operations, reinforcing its position as a leader in the cell and gene therapy industry.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £5.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has launched its Innovation and Technology Excellence Board (ITEB) to enhance its position as a leader in cell and gene therapy. The board, comprising experts in the field, will guide the company on technology priorities and innovation opportunities, aiming to improve scientific capabilities and maintain OXB’s market-leading status. This initiative is expected to strengthen OXB’s value proposition to clients and support the development of transformative therapies.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica PLC announced that its issued share capital as of May 31, 2025, consists of 106,093,858 ordinary shares, with no shares held in treasury. This figure represents the total number of voting rights in the company, which shareholders can use to determine their notification requirements under FCA rules.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has announced the grant of nil-cost share options under its 2024 Long Term Incentive Plan and Deferred Bonus Plan. These grants, aimed at aligning with the company’s growth strategy, focus on key metrics such as EBITDA margin and revenue growth, which are crucial for stakeholders and reflect the company’s commitment to incentivizing its leadership team.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Pippa Radcliffe, closely associated with the company’s Chief Innovation Officer, Dr. Kyriacos Mitrophanous, exercised 1,209 options and sold 1,209 shares at £2.9785 per share. This transaction, compliant with EU Market Abuse Regulation, reflects internal financial activities and may impact stakeholders’ perceptions of the company’s governance and financial health.
Oxford BioMedica PLC has announced a change in its major shareholders, with Briarwood Chase Management LLC acquiring a significant increase in voting rights, now holding 12.019% of the total. This acquisition indicates a strengthened position for Briarwood Chase Management in the company, potentially influencing future strategic decisions and impacting stakeholder interests.
Oxford Biomedica PLC has announced the notice of its Annual General Meeting (AGM) for 2025, which will be held on 11 June at its Oxford offices. The company has made the AGM notice and its 2024 Annual Report available to shareholders and submitted them to the Financial Conduct Authority for public access. This announcement is part of OXB’s ongoing commitment to transparency and stakeholder engagement, reflecting its strategic focus on maintaining strong governance and communication with its investors.
Oxford BioMedica PLC has announced a change in its voting rights, with Briarwood Chase Management LLC increasing its stake to 11.03% from a previous 10.54%. This acquisition of voting rights signifies a significant shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder interests.
Oxford BioMedica reported strong financial results for 2024, with a 44% increase in revenue to £128.8 million and an 81% organic growth rate. The company’s strategic expansion, including the acquisition of ABL Europe, has bolstered its global operations, particularly in viral vector platforms. The company achieved an operating EBITDA profit in the second half of 2024 and anticipates profitability for FY 2025. The growth reflects increased demand across all vector segments, with a notable rise in contracted client orders, signaling robust commercial momentum and positioning OXB for continued success in the cell and gene therapy market.
Oxford BioMedica PLC has announced a significant change in its shareholder structure, as Briarwood Chase Management LLC has increased its voting rights in the company to 10.54%, up from a previous 5.12%. This acquisition of voting rights highlights Briarwood Chase’s growing influence within the company, potentially impacting future strategic decisions and stakeholder interests.
Oxford Biomedica PLC announced the appointment of Colin Bond, a Non-Executive Director, to a similar role at Faron Pharmaceuticals Ltd, an AIM-listed company. This move reflects OXB’s strategic positioning within the cell and gene therapy industry, potentially strengthening its network and influence through leadership roles in related companies.